COLUMBUS, Ohio, April 19 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Imipramine Pamoate Capsules, 75mg, 100mg, 125mg and 150mg by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.
Full prescribing information for Imipramine Pamoate Capsules is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at
1.800.962.8364.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.
TOFRANIL-PM(R) is a registered trademark of Mallinckrodt, Inc.
CONTACT: For Roxane Laboratories: Angela Chirico, +1-614-241-4774,
Angela.Chirico@boehringer-ingelheim.com
Web site: http://www.Roxane.com/
